Expression Analysis of α5 Integrin Subunit Reveals Its Upregulation as a Negative Prognostic Biomarker for Glioblastoma.
Stupp protocol resistance
biomarker
glioblastoma
integrin α5
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
30 Aug 2021
30 Aug 2021
Historique:
received:
28
07
2021
revised:
26
08
2021
accepted:
27
08
2021
entrez:
28
9
2021
pubmed:
29
9
2021
medline:
29
9
2021
Statut:
epublish
Résumé
Integrin α5β1 was suggested to be involved in glioblastoma (GBM) aggressiveness and treatment resistance through preclinical studies and genomic analysis in patients. However, further protein expression data are still required to confirm this hypothesis. In the present study, we investigated by immunofluorescence the expression of integrin α5 and its prognostic impact in a glioblastoma series of patients scheduled to undergo the Stupp protocol as first-line treatment for GBM. The integrin α5 protein expression level was estimated in each tumor by the mean fluorescence intensity (MFI) and allowed us to identify two subpopulations showing either a high or low expression level. The distribution of patients in both subpopulations was not significantly different according to age, gender, recursive partitioning analysis (RPA) prognostic score, molecular markers or surgical and medical treatment. A high integrin α5 protein expression level was associated with a high risk of recurrence (HR = 1.696, 95% CI 1.031-2.792,
Identifiants
pubmed: 34577582
pii: ph14090882
doi: 10.3390/ph14090882
pmc: PMC8465081
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Société Française de Pharmacologie Oncologique
Organisme : Institut National Du Cancer
ID : INCA_11527
Organisme : Ligue Contre le Cancer
Organisme : Association pour la Recherche sur le Cancer
Organisme : Conseil National de la Recherche Scientifique
ID : 80/PRIME
Organisme : Université de Strasbourg
Références
Am J Pathol. 2005 Jul;167(1):193-211
pubmed: 15972964
Cancer Res. 2004 Jul 1;64(13):4648-53
pubmed: 15231677
Cancer Cell. 2010 Jan 19;17(1):98-110
pubmed: 20129251
Oncotarget. 2015 Oct 6;6(30):29675-93
pubmed: 26377974
J Neuropathol Exp Neurol. 2013 Mar;72(3):194-210
pubmed: 23399898
Cancers (Basel). 2021 Apr 09;13(8):
pubmed: 33918704
Cancer Res. 2014 Jan 1;74(1):3-7
pubmed: 24327727
Nat Rev Cancer. 2018 Sep;18(9):533-548
pubmed: 30002479
Eur J Cancer. 2013 Jun;49(9):2161-9
pubmed: 23566417
Clin Cancer Res. 2012 May 15;18(10):2930-42
pubmed: 22472177
Neuro Oncol. 2008 Feb;10(1):79-87
pubmed: 17993634
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Brain. 2013 Feb;136(Pt 2):564-76
pubmed: 23378223
Brain Pathol. 2008 Jul;18(3):378-86
pubmed: 18394009
Cancer Cell. 2017 Dec 11;32(6):856-868.e5
pubmed: 29198914
Neuro Oncol. 2015 May;17(5):708-17
pubmed: 25762461
Acta Neuropathol. 2012 Dec;124(6):763-75
pubmed: 23143192
J Clin Invest. 1991 Dec;88(6):1924-32
pubmed: 1721625
Mol Cancer Res. 2019 Feb;17(2):384-397
pubmed: 30266751
Int J Mol Sci. 2020 Jan 30;21(3):
pubmed: 32019108
Annu Rev Cell Dev Biol. 2011;27:321-45
pubmed: 21663444
Cancer Res. 2013 May 15;73(10):3145-54
pubmed: 23644530
Mol Ther Nucleic Acids. 2019 Sep 6;17:63-77
pubmed: 31226519
Curr Opin Cell Biol. 2011 Oct;23(5):630-7
pubmed: 21565482
Cancer Lett. 2016 Jul 1;376(2):328-38
pubmed: 27063097
Proc Natl Acad Sci U S A. 2015 Jan 20;112(3):851-6
pubmed: 25561528
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
Am Soc Clin Oncol Educ Book. 2012;:102-7
pubmed: 24451717
Nat Rev Cancer. 2008 Aug;8(8):604-17
pubmed: 18497750
Biol Open. 2012 Apr 15;1(4):329-40
pubmed: 23213423
Cancer Chemother Pharmacol. 2018 Aug;82(2):339-351
pubmed: 29905898
Oncotarget. 2016 Mar 22;7(12):15018-32
pubmed: 26918452
BMC Med. 2020 Jun 22;18(1):142
pubmed: 32564774
Am J Pathol. 2005 Nov;167(5):1379-87
pubmed: 16251422
Neurosurgery. 2001 Jan;48(1):151-7
pubmed: 11152340
Neuro Oncol. 2020 Aug 17;22(8):1073-1113
pubmed: 32328653
Am J Pathol. 1993 Jul;143(1):154-63
pubmed: 8317546
Eur J Cancer. 2015 Mar;51(4):522-532
pubmed: 25616647
N Engl J Med. 2014 Feb 20;370(8):699-708
pubmed: 24552317
Cancers (Basel). 2019 May 17;11(5):
pubmed: 31109009
Cell Rep. 2016 Dec 13;17(11):2994-3009
pubmed: 27974212
Nat Rev Cancer. 2010 Jan;10(1):9-22
pubmed: 20029421
Cell Mol Life Sci. 2021 Mar;78(6):2949-2962
pubmed: 33151388
J Neurosurg. 2011 Jul;115(1):3-8
pubmed: 21417701
Cancers (Basel). 2017 Sep 04;9(9):
pubmed: 28869579
Oncology. 2005;69 Suppl 3:4-10
pubmed: 16301830
Exp Neurol. 2012 Sep;237(1):46-54
pubmed: 22721769
Front Oncol. 2019 Sep 20;9:904
pubmed: 31616629
Cancer Ther. 2005;3A:325-340
pubmed: 16467916
Oncotarget. 2017 Aug 21;8(49):86947-86968
pubmed: 29156849
Front Pharmacol. 2015 Nov 24;6:279
pubmed: 26635609
JAMA. 2017 Dec 19;318(23):2306-2316
pubmed: 29260225
Lancet Oncol. 2014 Sep;15(10):1100-8
pubmed: 25163906
Cell Death Differ. 2016 Apr;23(4):640-53
pubmed: 26470725
J Clin Oncol. 2006 Jun 1;24(16):2563-9
pubmed: 16735709
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Cancer Res. 2012 Jul 15;72(14):3463-70
pubmed: 22593187
Gynecol Oncol. 2011 May 1;121(2):273-9
pubmed: 21276608
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
N Engl J Med. 2014 Feb 20;370(8):709-22
pubmed: 24552318